Date: 2016-10-04
Type of information: Licensing agreement
Compound:
Company: Amgen (USA - CA) Nuevolution (Denmark)
Therapeutic area: Cancer - Oncology - Neurological diseases
Type agreement: R&D licensing commercialisation
Action mechanism:
Disease:
Details: * On October 4, 2016, Nuevolution announced that Amgen and Nuevolution have entered into a multiple target research collaboration to develop and commercialize novel therapeutics in the areas of oncology and neuroscience. Nuevolution will apply its Chemetics® drug discovery platform to discover and advance potential therapeutics of interest to Amgen. The research collaboration brings together Nuevolution’s proprietary drug discovery platform with Amgen’s disease expertise and drug development capabilities. Nuevolution will be responsible for the early research phase and Amgen will work collaboratively with Nuevolution during late-stage research. Amgen will be fully responsible for preclinical development, clinical development and commercialization worldwide.
Financial terms: Under the terms of the agreement, Amgen has an exclusive option to obtain all rights to successfully developed programs. Nuevolution is eligible to receive a license fee payment upon option exercise and milestone payments upon achievement of specified research, development and commercial milestones, amounting up to $ 410 million per target. Nuevolution would also be entitled to receive royalties on future sales. Additional financial details are not being disclosed.
Latest news:
